The abovementioned mechanisms may partly explain our findings in improved MS-induced obesity and liver dysfunction after dulaglutide or resveratrol treatment via increased hepatic SIRT-1 expression. The gene discussed is SIRT1; the disease is obesity due to melanocortin 4 receptor deficiency.